Sanofi is seeking initial bids for its $20B consumer health arm as the company moves ahead with preparations for a potential listing of the arm, Bloomberg’s Pamela Barbaglia, Dinesh Nair, Francesca Veronesi, and Swetha Gopinath report. The drugmaker has asked potential suitors to make first-round bids by mid-July, according to people familiar with the matter. Advent International and France’s PAI Partners are seen as the most keen on the asset, the people say.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi a winner from ‘highly impressive’ Alnylam data, says Citi
- Sanofi, Biovac spearhead polio vaccine manufacturing capabilities in Africa
- Innate Pharma announces updated results from SAR443579/IPH6101
- Novavax price target raised to $18 from $12 at BofA
- Sanofi’s Dupixent Awaits Extended FDA Review